[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640974":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":187,"collaborators":26,"id":189,"slug":190,"hasResults":191,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":191,"sex":197,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":26,"studyType":203,"phases":204,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":145,"whyStopped":26,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},{"fullName":5,"class":6},"Sun Pharma Japan Limited","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Deuruxolitinib 8 mg","EXPERIMENTAL","Participants in this arm will receive deuruxolitinib 8 mg administered orally twice daily (BID) during the 24-week double-blind treatment period and continue to receive deuruxolitinib 8 mg administered orally BID up to 52 weeks",[13],"Drug: Deuruxolitinib",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants in this arm will receive matching placebo administered orally BID during the 24-week double-blind treatment period and then receive deuruxolitinib 8 mg administered orally BID up to 52 weeks.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Deuruxolitinib","Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Deuruxolitinib matching placebo will be dosed orally as tablets for up to 24 weeks and then deuruxolitinib will be dosed for up to 52 weeks",[15],[23],[32,45,54,63,72,81,90,99,108,117,126,130,134,143,159,165,174,178],{"facility":33,"status":34,"city":35,"state":26,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":26},"Study Site 102","NOT_YET_RECRUITING","Asahikawa","078-8510","Japan","JP",{"type":40,"coordinates":41},"Point",[42,43],142.36489,43.77063,{"lat":43,"lon":42},{"facility":46,"status":34,"city":47,"state":26,"zip":48,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":26},"Study Site 117","Bunkyō City","113-8431",{"type":40,"coordinates":50},[51,52],139.4217,35.5331,{"lat":52,"lon":51},{"facility":55,"status":34,"city":56,"state":26,"zip":57,"country":37,"countryCode":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":26},"Study Site 119","Ebina","243-0432",{"type":40,"coordinates":59},[60,61],139.39651,35.38121,{"lat":61,"lon":60},{"facility":64,"status":34,"city":65,"state":26,"zip":66,"country":37,"countryCode":38,"cosmosGeoPoint":67,"geoPoint":71,"contacts":26},"Study Site 101","Hamamatsu","431-3192",{"type":40,"coordinates":68},[69,70],137.73333,34.7,{"lat":70,"lon":69},{"facility":73,"status":34,"city":74,"state":26,"zip":75,"country":37,"countryCode":38,"cosmosGeoPoint":76,"geoPoint":80,"contacts":26},"Study Site 116","Ishikawa","920-0293",{"type":40,"coordinates":77},[78,79],127.82139,26.42333,{"lat":79,"lon":78},{"facility":82,"status":34,"city":83,"state":26,"zip":84,"country":37,"countryCode":38,"cosmosGeoPoint":85,"geoPoint":89,"contacts":26},"Study Site 112","Kitakyushu","807-8556",{"type":40,"coordinates":86},[87,88],130.85034,33.85181,{"lat":88,"lon":87},{"facility":91,"status":34,"city":92,"state":26,"zip":93,"country":37,"countryCode":38,"cosmosGeoPoint":94,"geoPoint":98,"contacts":26},"Study Site 118","Kōtoku","136-0075",{"type":40,"coordinates":95},[96,97],143.14297,42.50417,{"lat":97,"lon":96},{"facility":100,"status":34,"city":101,"state":26,"zip":102,"country":37,"countryCode":38,"cosmosGeoPoint":103,"geoPoint":107,"contacts":26},"Study Site 110","Kurashiki","701-0192",{"type":40,"coordinates":104},[105,106],133.76667,34.58333,{"lat":106,"lon":105},{"facility":109,"status":34,"city":110,"state":26,"zip":111,"country":37,"countryCode":38,"cosmosGeoPoint":112,"geoPoint":116,"contacts":26},"Study Site 113","Kurume","830-0011",{"type":40,"coordinates":113},[114,115],130.51667,33.31667,{"lat":115,"lon":114},{"facility":118,"status":34,"city":119,"state":26,"zip":120,"country":37,"countryCode":38,"cosmosGeoPoint":121,"geoPoint":125,"contacts":26},"Study Site 107","Kyoto","606-8507",{"type":40,"coordinates":122},[123,124],135.75385,35.02107,{"lat":124,"lon":123},{"facility":127,"status":34,"city":128,"state":26,"zip":129,"country":37,"countryCode":38,"cosmosGeoPoint":26,"geoPoint":26,"contacts":26},"Study Site 106","Mitaka-shi","181-8611",{"facility":131,"status":34,"city":132,"state":26,"zip":133,"country":37,"countryCode":38,"cosmosGeoPoint":26,"geoPoint":26,"contacts":26},"Study Site 114","Miyagi-gun","981-0112",{"facility":135,"status":34,"city":136,"state":26,"zip":137,"country":37,"countryCode":38,"cosmosGeoPoint":138,"geoPoint":142,"contacts":26},"Study Site 104","Niigata","951-8520",{"type":40,"coordinates":139},[140,141],139.04125,37.92259,{"lat":141,"lon":140},{"facility":144,"status":145,"city":146,"state":26,"zip":147,"country":37,"countryCode":38,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Study Site 109","RECRUITING","Osaka","542-0081",{"type":40,"coordinates":149},[150,151],135.50107,34.69379,{"lat":151,"lon":150},[154],{"name":155,"role":156,"phone":157,"phoneExt":26,"email":158},"Inui","CONTACT","+81-6-6484-5755","JPS.clinicaltrial@sunpharma.com",{"facility":160,"status":34,"city":146,"state":26,"zip":161,"country":37,"countryCode":38,"cosmosGeoPoint":162,"geoPoint":164,"contacts":26},"Study Site 108","545-0051",{"type":40,"coordinates":163},[150,151],{"lat":151,"lon":150},{"facility":166,"status":34,"city":167,"state":26,"zip":168,"country":37,"countryCode":38,"cosmosGeoPoint":169,"geoPoint":173,"contacts":26},"Study Site 103","Sapporo","060-8648",{"type":40,"coordinates":170},[171,172],141.35,43.06667,{"lat":172,"lon":171},{"facility":175,"status":34,"city":176,"state":26,"zip":177,"country":37,"countryCode":38,"cosmosGeoPoint":26,"geoPoint":26,"contacts":26},"Study Site 105","Shinjuku-Ku","160-0023",{"facility":179,"status":34,"city":180,"state":26,"zip":181,"country":37,"countryCode":38,"cosmosGeoPoint":182,"geoPoint":186,"contacts":26},"Study Site 111","Ube","755-8505",{"type":40,"coordinates":183},[184,185],131.25111,33.94306,{"lat":185,"lon":184},{"type":188,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100640974","phase-3-study-to-evaluate-the-efficacy-and-safety-of-deuruxolitinib-in-japanese-adults-with-severe-alopecia-areata-100640974",false,"NCT07617597","Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata","A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period","THRIVE-AAJP","Inclusion Criteria:\n\n* Written informed consent has been obtained.\n* Japanese subjects with severe alopecia areata who are between 18 and 65 years of age, inclusive, at the time of informed consent.\n* Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months.\n* SALT score of 50 or more at both Screening and Baseline.\n\nExclusion Criteria:\n\n* Treatment with systemic immunosuppressive medications or agents, including Janus kinase inhibitors, within 4 months prior to randomization.\n* Treatment with biologics within 6 months prior to Screening.\n* Positive test results for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus at Screening.\n* History of active tuberculosis, a positive interferon gamma release assay at Screening, or evidence of tuberculosis-related lesions on chest radiography.\n* Clinically significant hematologic abnormalities, hepatic impairment, or renal impairment at Screening.","ALL","18 Years","65 Years",{"count":201,"type":202},78,"ESTIMATED","INTERVENTIONAL",[205],"PHASE3","This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.",[208],"Alopecia Areata",[210,211,212,213,214],"alopecia areata","severe alopecia areata","hair loss","deuruxolitinib","JAK inhibitor","2026-06-30",{"date":217,"type":218},"2026-07-02","ACTUAL",{"date":220,"type":218},"2026-06-19",{"date":222,"type":202},"2028-09",{"name":5,"class":6},18]